The role of mullerian inhibiting substance in female reproduction
Review
OA: closed
public-domain-us
⚙
AI-generated summary
by qwen3.7-flash, 2026-09-07
ⓘ
This review examines Mullerian inhibiting substance as a marker of female reproductive function, noting its association with endometriosis, polycystic ovarian syndrome, and in-vitro fertilization outcomes.
⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-09
· read from full text
ⓘ
This review examines the biological functions and clinical utility of Mullerian inhibiting substance as a marker for female reproductive health. The authors note that while the hormone mediates follicle recruitment and selection, its exact mechanisms remain unclear, though it is characteristically elevated in polycystic ovarian syndrome and associated with conditions like functional hypothalamic amenorrhea and obesity. The paper highlights its correlation with in-vitro fertilization outcomes but emphasizes the need for assay standardization before widespread clinical implementation. Relevance to endometriosis: listed as one condition where Mullerian inhibiting substance changes have been observed, though the paper's main focus is broader reproductive function and ovulatory disorders.
Abstract
PURPOSE OF REVIEW: To review the role of mullerian inhibiting substance in the context of female reproduction.
RECENT FINDINGS: Serum and follicular fluid mullerian inhibiting substance can be measured by commercially available enzyme-linked immunosorbent assay kits. Mullerian inhibiting substance is secreted from small antral follicles with minimal fluctuation throughout the menstrual cycle. The exact biological functions of mullerian inhibiting substance are uncertain; however, mullerian inhibiting substance most likely mediates follicle recruitment and selection, and may inhibit aromatase activity. Most data suggests an interaction between follicle-stimulating hormone, and mullerian inhibiting substance although the exact nature of the relationship is unknown. Mullerian inhibiting substance is characteristically elevated in polycystic ovarian syndrome, and may be associated with other features of polycystic ovary syndrome such as insulin resistance, hyperandrogenemia, and the degree of anovulation. Mullerian inhibiting substance changes have also been associated with functional hypothalamic amenorrhea, premature ovarian failure, endometriosis and obesity. Mullerian inhibiting substance has been studied extensively in the context of in-vitro fertilization and has been correlated with several outcome parameters.
SUMMARY: Mullerian inhibiting substance is gaining acceptance as a useful marker of female reproductive function, especially with ovulatory disorders and IVF outcomes. Mullerian inhibiting substance offers several advantages to existing screening tests, but establishment of an assay standard should be considered before widespread clinical implementation becomes viable.
Full text
1,786 characters
· extracted from
oa-doi-fallback
· click to expand
The role of mullerian inhibiting substance in female reproduction
- Gary S Nakhuda
Purpose of review
To review the role of mullerian inhibiting substance in the context of female reproduction.
Recent findings
Serum and follicular fluid mullerian inhibiting substance can be measured by commercially available enzyme-linked immunosorbent assay kits. Mullerian inhibiting substance is secreted from small antral follicles with minimal fluctuation throughout the menstrual cycle. The exact biological functions of mullerian inhibiting substance are uncertain; however, mullerian inhibiting substance most likely mediates follicle recruitment and selection, and may inhibit aromatase activity. Most data suggests an interaction between follicle-stimulating hormone, and mullerian inhibiting substance although the exact nature of the relationship is unknown. Mullerian inhibiting substance is characteristically elevated in polycystic ovarian syndrome, and may be associated with other features of polycystic ovary syndrome such as insulin resistance, hyperandrogenemia, and the degree of anovulation. Mullerian inhibiting substance changes have also been associated with functional hypothalamic amenorrhea, premature ovarian failure, endometriosis and obesity. Mullerian inhibiting substance has been studied extensively in the context of in-vitro fertilization and has been correlated with several outcome parameters.
Summary
Mullerian inhibiting substance is gaining acceptance as a useful marker of female reproductive function, especially with ovulatory disorders and IVF outcomes. Mullerian inhibiting substance offers several advantages to existing screening tests, but establishment of an assay standard should be considered before widespread clinical implementation becomes viable.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.
My notes (saved in your browser only)
⚙
Ask this paper
AI returns verbatim quotes from the full text
· source: oa-doi-fallback
ⓘ
Condition tags
endometriosis
MeSH descriptors
Anti-Mullerian Hormone
Infertility, Female
Oocytes
Anti-Mullerian Hormone
Anti-Mullerian Hormone
Biomarkers
Biomarkers
Female
Female
Fertilization in Vitro
Fertilization in Vitro
Humans
Humans
Infertility, Female
Infertility, Female
Oocytes
Oocytes
Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Polycystic Ovary Syndrome
Citation neighborhood
(no data yet)
We don't have any in-corpus citations linked to this paper yet.
The paper's references may be in our DB but unresolved to
``paper_id`` (resolution happens at ingest when the cited DOI
matches a row we already have). Run the cross-source citation
reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-11-04T06:09:08.831786+00:00
- pubmed
- last seen: 2026-10-08T21:05:19.467219+00:00
- unpaywall
- last seen: 2026-11-04T06:24:41.714486+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine